IMPORTANCE Dementia care management (DCM) can increase the quality of care for people with dementia. Methodologically rigorous clinical trials on DCM are lacking.
D ementia is a public health priority that affects 47.5 million people worldwide. 1 The rapidly growing number of people with dementia presents a challenge to the health care systems. People with dementia need comprehensive medical, nursing, psychological, and social support to delay the progression of disease and sustain autonomy and social inclusion. Primary care has been identified as the first point of contact for people with dementia and is thus a promising setting for identification, comprehensive needs assessment, and initiating dementia-specific treatment and care. 2 However, primary care systems worldwide are insufficiently prepared for these tasks. [3] [4] [5] [6] Evidence-based interventions alleviate the burden of disease, as no curative treatment is currently available. Involving caregivers in intervention is important because they provide the largest proportion of care for people with dementia. The burden of informal care [7] [8] [9] is the main determinant of nursing home admissions of people with dementia, 10,11 and informal care contributes the most to total care costs. 12, 13 General challenges in the management of dementia include providing antidementia drug treatment, addressing neuropsychiatric symptoms and behavioral problems, reducing inappropriate psychoactive medication use, and managing caregiver burden. 14 Collaborative care programs address these challenges. There is some evidence that programs for general practitioner (GP)-based dementia care can be successfully implemented into health systems. 15 However, presently the scientific evidence does not match the enthusiasm for these programs. 16 There is a need to test the effectiveness of care management before implementation in primary care.
17
A Cochrane review 18 from 2015 analyzing 13 randomized clinical trials revealed beneficial effects of care management, specifically in reducing patients' behavior disturbance, and caregivers' burden and depression as well as in improving caregivers' well-being and social support. However, there is heterogeneity in interventions, study designs, sample size, and outcomes measured. Thus, the review concluded that studies that are rigorous in design and intervention delivery are needed.
18
Intervention modules and a standard set of outcome measures should furthermore be clearly defined to improve comparability.
18-20
The present randomized clinical trial describes the effectiveness of dementia care management (DCM) on relevant patient-and caregiver-oriented outcomes, including (1) quality of life, (2) caregiver burden, (3) behavioral and psychological symptoms of dementia, (4) pharmacotherapy with antidementia drugs, and (5) use of potentially inappropriate medication (PIM). Dementia care management uses a well-defined, computer-supported, 21 and model-based intervention 22 implemented by specifically trained nurses.
23

Methods
Trial Design
The Dementia: Life-and Person-Centered Help in MecklenburgWestern Pomerania (DelpHi) trial was a pragmatic, GP-based, cluster-randomized intervention study with 2 arms, an intervention group and a care as usual (CAU) group. The study protocol was approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania, Germany (registry number BB 20/11). The reporting of this study follows the CONSORT statement 24 and its extensions regarding cluster-randomized, 25 pragmatic trials 26 with nonpharmacologic treatments. 27 The design, eligibility and inclusion criteria, intervention, and baseline characteristics of the trial have been described in detail elsewhere. [21] [22] [23] 28 The full trial protocol is available in Supplement 1.
Clusters
General practices were the unit of randomization and determined the patients' group status. A total of 854 GPs in 5 municipalities of Mecklenburg-Western Pomerania were invited to participate by mail. General practitioners expressing an interest in the study were visited by the investigators to convey additional detailed information about the study. Finally, 136 GPs (15.9%) gave written informed consent to participate and agreed to adhere to the DelpHi trial protocol. There were no restrictions regarding the GPs' treatment of patients.
Participants
General practitioners assessed the eligibility of patients (≥70 years, living at home) and systematically screened patients who met the inclusion criteria using the DemTect procedure. 29 This interview-based instrument is widely used for dementia screening in GP practices in Germany and is more sensitive than the Mini-Mental State Examination for detecting milder forms of cognitive impairment (DemTect, 98% vs Mini-Mental State Examination, 46%). 30, 31 Thus, it is possible that some patients screened positive for dementia by the DemTect procedure are not considered cognitively impaired according to the Mini-Mental State Examination (score 27 to 30 of 30). Study enrollment started January 1, 2012, and ended December 31, 2014. The follow-up period ended on March 31, 2016. Patients who screened positive for dementia were informed about the study by their GP, invited to participate, and asked to provide written informed consent. If the patients listed a caregiver, he or she was asked to participate as well. When patients were unable to provide written informed consent, their legal representative was asked to sign the consent form on their
Key Points
Question What is the effect of dementia care management, a model of collaborative care, on the treatment and care of people with dementia and their caregivers in primary care?
Findings In this randomized clinical trial of 634 people with dementia, dementia care management significantly reduced neuropsychiatric symptoms and caregiver burden and increased use of antidementia drugs compared with care as usual. Dementia care management was found to be a safe intervention.
Meaning Dementia care management may significantly improve the outcomes of treatment and care among people with dementia and caregiver burden and should be incorporated into routine care.
behalf. General practitioners received allowances for screening (€10 [US $11.15] per patient) and study enrollment (€100 [US $111.54] per patient).
Intervention
Dementia care management aims to provide optimal care by integrating multiprofessional and multimodal strategies for improving patient-and caregiver-related outcomes within the framework of the established health care and social service system. It was developed according to current guidelines, 32, 33 targeted at the individual participant level, and delivered at patients' homes by 6 nurses with dementia-specific qualifications supported by a computer-based intervention-management system (IMS) to improve systematic identification of patients' and caregivers' unmet needs. The nurses conducted an in-depth assessment. Based on these data, the IMS generated an individual preliminary intervention task list, and the nurses discussed and finalized the task list in a weekly interdisciplinary case conference with a nursing scientist, a neurologist/ psychiatrist, a psychologist, and a pharmacist. Afterwards, the list of intervention tasks was summarized in a semistandardized GP information letter. This letter was then discussed between the GP and nurse to establish an individual treatment plan. During the first 6 months of the intervention period, the nurse conducted 6 home visits with an average duration of 1 hour, carrying out his or her standard intervention tasks in close cooperation with the caregiver, the GP, and health care and social service professionals. During the subsequent 6 months, the study nurse monitored the completion of all intervention tasks. In line with the Pacala scale 34 for intensive case managements, each study nurse delivered intervention to, on average, 60 patients with dementia. Training, intervention, and the IMS are described in more detail elsewhere 28, 35 and in the eAppendix in Supplement 2.
Outcomes
The primary outcomes were assessed within identical, standardized, computer-assisted face-to-face interviews at the patients' homes by specifically qualified nurses over an average of 3 separate visits at baseline and 12 months after baseline and pertain to the individual patients' (1) ; (4) use of pharmacotherapy with antidementia drugs, which included the following substances recommended by relevant guidelines: donepezil, galantamine, rivastigmine, and memantine; and (5) use of PIM, which is defined as a drug for which the risk of an adverse drug effect outweighs the clinical benefit and evaluated using the PRISCUS criteria.
39-41 The predefined secondary outcomes included cognitive status, measured using the Mini-Mental State Examination
42
; activities of daily living, measured using the Bayer-Activities of Daily Living Scale; and health care resource use, especially institutionalization.
43,44
Sample Size
No previous data on the main outcome measures were available for sample size calculation. Therefore, sample size was estimated based on theoretical assumptions. In the design, the minimally important difference for determining the effectiveness was considered to be of at least a small effect, defined by
. 45 Comparing 2 groups at a significance level of α = .05, assuming a statistical power of 80% and an intraclass correlation with clustering by GP practice of 0, a sample size of 310 persons per group would have been sufficient. 45 Considering the longitudinal design, we accounted for a loss over time of 35% (eg, death or withdrawal of informed consent) and determined that 477 persons per group with complete data sets would have been needed to be included in the study. We estimated that GPs would identify 1000 patients over the course of 2 years. Recruitment turned out to be slower than expected. Thus, recruitment was prolonged from 2 to 3 years. The achieved sample size allows to detect a medium effect size (Cohen d = 0.5).
45
Randomization and Allocation
We used simple 1:1 randomization without stratification or matching. This procedure was sufficient because of the high number of expected clusters in our study. 46 General practitioners were not informed of their randomization status. However, because of the type of intervention, GPs became aware of their status throughout the course of the study. Patients were recruited and enrolled by participating GPs but allocated to the study group by study center. Because baseline assessment, primary outcome assessment, and delivery of intervention needed to be performed by the same nurses, blinding was not possible.
Statistical Methods
Descriptive Statistics
To describe the sample, metric variables were summarized as means and SD, and nominal variables were presented as proportions. Baseline and follow-up values were compared using paired t tests or McNemar tests, as applicable.
Primary Analyses
The primary analyses (intention to treat [ITT] and per protocol) included generalized regression models, with a model specification corresponding to the scale level of the outcome variable. The ITT analysis was performed as modified ITT for all cases with valid baseline data, 47 and the per-protocol analysis included complete cases only. Missing data in the follow-up variables were imputed by multiple imputations via chained equations. The outcome variable at follow-up was the dependent variable, and study group was the predictor of interest. To account for the stochastic dependency of patients treated by the same GP, GPs were included as random effects. The baseline value of the outcome variable was included as a covariate to reduce residual variance and to account for interindividual variance at baseline. Furthermore, age, sex, and living situation (alone vs not alone) were included as covariates. A positive intervention effect was defined as a significant regression coefficient of the study group variable. Sensitivity analyses were performed by introducing random slopes for the difference of DCM vs CAU and the baseline variable of the outcome and recalculating the P values and 95% CIs by bootstrapping (2000 replications). All P values for the primary analyses are 1-sided. Data analysis and management were conducted using Stata version 13.1 (StataCorp). Details of the statistical analyses are provided in Supplement 1.
Secondary Analyses
Because the intervention targeted the patients' entire social system, exploratory prior analyses, prespecified in the analysis plan, were conducted by stratifying the models by patients' living situation, identifying whether the intervention would show stronger effects in persons living alone or not living alone.
Results
Participant Flow
The CONSORT statement is illustrated in the Figure. Overall, 634 patients provided written informed consent, and a total of 407 (64.2%) received the intended treatment (DCM, 291 ). There were no statistical differences between patients assessed at follow-up (n = 407) and those who dropped out before follow-up (n = 227) in age, sex, and DemTect score (eTable 1 and eTable 2 in Supplement 2). The intervention was safe, as no dropout was reported because of GPs' advice or problems with the intervention reported by the patients with dementia or the caregiver. There was no significant effect of the study group on mortality.
Baseline Data
Participant characteristics at baseline and follow-up are summarized in Table 2 . Primary outcome measures for baseline and follow-up are given by group in Table 3 . The groups did not differ significantly according to primary outcomes and sociodemographic variables (eTable 3 in Supplement 2) in the ITT analyses data set. In the per-protocol analyses set, the CAU group reported a significantly higher quality of life.
Outcomes and Estimation
In the primary ITT analyses, a significant decrease in patients' behavioral and psychological symptoms of dementia (b = −7.45; 95% CI, −11.08 to −3.81; P < .001) and caregiver burden (b = −0.50; 95% CI, −1.09 to 0.08; P = .05) was observed in the intervention group compared with CAU. Sensitivity analyses confirmed the results of the ITT analyses. As expected, the clinical characteristics showed serious clustering, and sociodemographic variables, such as sex, age, and living status, were not GP-dependent. The per-protocol analyses, sensitivity analyses, and the intraclass correlations for the main outcomes are reported in eTable 4 in Supplement 2.
Discussion
In our study, DCM was beneficial for optimizing treatment and care in patients with dementia. We found medium to large effects of DCM for community-dwelling patients with dementia in primary care on behavioral and psychological symptoms, caregiver burden, and pharmacologic treatment with antidementia drugs. Referring to neuropsychiatric symptoms measured by the Neuropsychiatric Inventory, a decrease in 4 points would be regarded as clinically meaningful.
38
In our analysis, DCM reduced neuropsychiatric symptoms by 8 points, with a larger effect size compared with previous studies included in the Cochrane review by Reilly et al 48 (standardized mean difference, −0.20; 95% CI of difference, −0.41 to 0.01; n = 368; I 2 = 83%; P = .06). Referring to caregiver burden, the effect size of the DCM was medium but larger when compared with other studies (−0.18 vs −0.07). 48 Thus, our results indicate meaningful clinical relevance. The study methods were in line with the demand to use standardized sets of outcome measures 20 and well-defined interventions 19 to improve comparability across studies, and our results contribute empirical evidence to currently inconclusive research 18 on DCM approaches in primary care. The results suggest that DCM increased the quality of dementia care. Improvements included a higher use of antidementia drugs. Although this is a simple proxy for good medical dementia care, the data do not indicate whether drug A small effect on quality of life was restricted to patients not living alone. This result should not be overestimated because validity and reliability of quality of life measures in people with dementia are limited. However, this finding implies that further analyses could identify target groups with an increased benefit. We speculate that the effectiveness of DCM could be associated with socioeconomic status, functional ability, or severity of dementia.
There was no effect of DCM on the frequency of PIMs. This is unexpected because comprehensive medication management was part of the intervention. We speculate that the intensity was probably too low in this trial because recommendations to the GP regarding pharmacologic treatment were provided only once. An effective reduction of PIMs may require a higher intensity of care management and follow-up reviews. 54 
Limitations
Screening and recruitment were part of routine care so that selection bias cannot be ruled out. Any systematic control mechanisms would have interfered with GPs' routine, causing adverse effects, including dropout of GPs. However, all participating GPs agreed to recruit systematically while adhering to the requirements of the study design.
The number of participants was imbalanced between the intervention and control groups. Fewer GPs were randomized to the control group. Furthermore, there was the tendency that GPs in the control group included less patients. We expect that during the trial, GPs noticed their assignment, which resulted in a loss of motivation for an inclusion of further patients. However, there were no significant group differences according to primary outcomes or sociodemographic variables.
The DelpHi trial was not a diagnostic trial. The identification of patients with dementia was based on a screening instrument. A state-of-the-art diagnostic procedure was not required. However, the DemTect was designed for this specific purpose and is widely used in routine care. 30, 55, 56 Furthermore, the main analysis was ITT, and any false positives would have caused an underestimation of the intervention effect.
Generalizability
The study was incorporated into routine care as closely as possible so that the external validity of the results is high. However, because of the rigorous design in the context of this trial, there were restrictions in time, length, and content of DCM activities. In routine care, nurses have more freedom to decide what, when, and how activities are performed. Additionally, generalizability might be limited because of the region and health care system being studied. It is possible that differences in access and availability of health care resources in other health care systems may affect the effectiveness. However, challenges of dementia care are mainly triggered by the disease itself and require similar resources that are available in different regions and health systems. A brief summary is given here.
The study plan was designed to assemble a general physician-based epidemiological cohort of people above the age of 70 who live at home (DelpHi cohort). These people are systematically screened for eligibility to participate in a trial of dementia care management (DelpHi trial, eligibility criteria: age 70+. living at home, dementia screening positive). The trial is a complex, cluster-randomised, controlled intervention trial with two arms (intervention and control), assessments at baseline and yearly follow-up. The study was designed to test the efficacy and efficiency of implementing a subsidiary support system for persons with dementia who live at home. This subsidiary support system is initiated and coordinated by a dementia care manager: a nurse with dementia-specific qualifications who delivers the intervention according to a systematic, detailed protocol. The intervention starts right after baseline assessment and is planned to last 6 months. The follow-up assessment that is planned for the evaluation of efficacy and efficiency is planned 12 months after baseline assessment.
The primary outcomes in this complex intervention trial are quality of life and healthcare for patients with dementia and their caregivers. These are multidimensional outcomes with a focus on four dimensions: (1) quality of life, (2) Utilisation of health care resources will be assessed according to GP and specialist visits, outpatient treatments, inpatient treatments, hospitalisations, nursing home admissions, therapeutic appliances and provision of informal care. 6. Medications will be assessed by the DCM, who will conduct an information technology-supported standardised home medication review at the patient's home with subsequent medication management by the patient's local pharmacy regarding the frequency of drug-related problems, intake of PIMs, clinically relevant drug-drug interactions, adherence, adherence to supportive activities (that is, medication plan, drug dispenser, support by care service, reduction of the number of drugs taken and home medication review).
Preliminary Remarks for the statistical analysis plan
The statistical analyses plan was written in its first version in November/Dezember 2015 and was then finalized in March 2016. The follow-up data was analyzed beginning April 2016 until October 2016.
Thus, the analysis plan was written before analyzing the follow-up data. However, the baseline data was analyzed since 2013 and the design paper was published in 2011. At the time of the publication of the design paper, the study statistician (Johannes Hertel) was not yet employed in the DZNE and was therefore neither involved in designing the DelpHi-MV trial, nor in writing the design paper. The statistical analyses plan therefore is not coherent with the design paper in several points. The statistical analyses plan here only describes the efficacy analyses regarding the primary endpoints of the DelpHi trial.
The DelpHi cohort consists of individuals (above 70 years) who were screened positively on dementia.
The sampling was done in primary care in the general practice (GP). Additionally, if possible, the principle care giver was included into the study. The GP was randomized by fair coin tossing to care as usual or intervention group. Thus, DelpHi is a cluster randomized clinical trial and all analyses have to respect the stochastic dependency of the data on the GP clustering. The randomization was done before baseline assessment of the individuals and the intervention cannot be classified as blinded, neither on the level of the GP, nor on the level of the study participant. The DelpHi trial can be classified as exploratory as no effect sizes a priori were known for the complex intervention that was performed. Moreover, the trial is clearly a pragmatic trial as it is implemented in primary care. Thus, the internal validity is potentially limited and several sources of bias (especially selection, attrition and performance bias) bias have to be assessed.
The power calculations mentioned in the design paper did not reflect the clustering of the data. The power of cluster randomized trials is not only a function of effect size, significance level and sample size, but dependent on the parameters of the concrete parameters of the clustering which were not known before sampling the data. In general, the power of a cluster randomized trial is lower in comparison to a randomized trial of equal sample size. The concrete loss of power is a function of the intra-class correlation (ICC) of the outcome, the number and size of the clusters and the variability of the cluster sizes in the sample. It is known that with higher ICC the statistical power gets lower. If the ICC would be zero, normal power calculations apply. Thus, the sample size calculations noted in the design paper can be seen as upper bounds assuming that the ICC is zero for all outcome parameters.
More accurate power calculations were therefore performed during the baseline sampling when first estimates of the ICCs where known and can be found at the end of this document.
Analysis Plan
Definition of the Primary Efficacy Endpoints
The design paper defined four dimensions of primary endpoints:
(1) Quality of life (2) Caregiver burden (3) Behavioural and psychological symptoms of dementia (4) Pharmacotherapy with an antidementia drugs and prevention or suspension of potentially inadequate medication (PIM)
The fourth dimension includes two outcome measurements (antidementia drug treatment) and the suspension of PIM, thus, in total five outcome variables are derived. The first follow-up values on these dimensions (12 months after baseline) were defined as efficacy endpoints.
Operationalization of the Primary Endpoints (1) Quality of life
Quality of life was measured using the Quality of Life in Alzheimer's Disease instrument [1] . It consists of 13 Lickert scale items that covers the following dimensions: physical health, energy level, mood, living situation, relationship with family members, caregivers and friends, memory as well as the ability to meaningful activities and financial situations. This instrument has been shown reliable and valid ratings by persons with mild to moderate dementia. Higher scores indicated better quality of life. The mean response on all answered items is used as outcome measurement, regardless whether the response on single items is missing. The mean response is treated as an interval scaled metric outcome.
(2) Caregiver burden
Caregiver burden was measured via the Berliner Inventar zur Angehörigenbelastung (BIZA-D) [2] .
The BIZA-D was developed to assess objective and subjective burden due to caring for a PWD. It consists of 88 items covering 20 dimensions of caregiver burden. Objective burden is divided into six dimensions, assessed by 25 items: 1) basic care tasks, such as supporting eating and hygiene (seven items), 2) extended care tasks, such as supporting grocery shopping and legal affairs (three items), 3) motivation and guidance (four items), 4) emotional support (four items), 5) support of the maintenance of social contacts (3 items) and 6) supervision (four items). Each item has to be rated regarding the frequency of the support needed on a 5-point scale (e.g., supervision: Does the patient need this type of support 1=always, 2=mostly, 3=partly, 4=hardly, 5=not at all). Subjective burden is divided into a) the subjective burden of behavior change (six dimensions: burden due to cognition with four items, aggression with five items, depression with four items, disorientation with five items, late symptoms with three items, and loss of relationship with five items); b) the subjective burden of perceived conflicts between needs and responsibilities to care (six dimensions: burden due to personal constraints with nine items, negative evaluation of one's own caring with four items, missing social appreciation with four items, financial losses with four items, personal development with three items, missing institutional support with three items); and c) role conflicts (two dimensions; professional role conflicts with four items, family role conflicts with five items).
From analyzing the baseline data, it was known that the 20 sum scores of the scales were highly intercorrelated with each other. Consequently, in a principle component analysis, one principle component explaining 38.6% of variance dominated. As the sequential analyses of each scale would lead to massive multiple testing, the first principle component of the BIZA-D is chosen as outcome parameter, representing a compound measure of the caregiver burden. This compound measurement is treated as an interval scaled metric outcome.
(3) Behavioral and psychological symptoms of dementia
The behavioral and psychological symptoms of dementia were operationalized by the Neuropsychiatric Inventory (NPI), developed by the Alzheimer's Disease Cooperative Study investigators [3] . The NPI represents an interview by proxy on twelve dimensions of neuropsychiatric behaviors, i.e. delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The severity and frequency of each neuropsychiatric symptom are rated on the basis of scripted questions administered to the patient's caregiver. A total NPI score is calculated as the product sum of the frequency by severity scores within each domain. The NPI also assesses the amount of caregiver distress engendered by each of the neuropsychiatric disorders, but the caregiver distress scores were not used in our analysis. The total score of all twelve scales were used as interval scale metric outcome variable as supposed in the NPI manual.
(4) Pharmacotherapy with an antidementia drugs
Antidementia drug treatment was defined as in Wucherer et al. [4] The computer-based collection of primary data on medication in the context of the home medication review includes both prescription drugs (Rx) and over-the-counter (OTC) drugs. The assignment was integrated using a master file of the Pharmaceutical Index (GKV-Arzneimittelindex) [5] . Active substances were coded according to the Anatomical Therapeutic Chemical (ATC) classification system (German Modification) [6] . The outcome variable is dichotomous with individuals taking one of the following drugs (N06DA02: donepezil; N06DA03: rivastigmine; N06DA04: galantamine; N06DA52: donepezil and memantine; N06DX01: memantine) coded with "1". Individuals not taking one these drugs were coded with "0".
(5) Prevention or suspension of potentially inadequate medication (PIM)
Suspension of PIM taking was defined according to Priscus list [7] . A list of all ATC codes considered as PIMs is given in the appendix. From the baseline analyses, it was known that multiple prescriptions of PIMs are seldom in the study population (Wucherer et al. 2016 ). Thus, for efficacy analyses, we dichotomize the PIM prescriptions: "1"= one or more PIMs prescribed; "0"= no PIM prescribed.
Efficacy Analyses
Per protocol analyses 2.3.1.1 Definition of the analyses set
We define the per protocol analysis as complete case analyses. The only reason not to be included into the per-protocol analysis is due to missing data in the baseline assessment or the follow-up assessment.
Contaminations by changing treatment assignments after randomization are impossible due to the study design. The main reason for missing data is supposed to be drop-out because of death or withdrawal of informed consent.
Primary efficacy Analyses
For primary efficacy analyses, for each of the main outcome of the study a separate generalized linear mixed model is fitted with the model specification corresponding to the scale level of the outcome under investigation. Thus, for quality of life, caregiver burden and neuropsychiatric symptoms linear mixed regressions will be used assuming a Gaussian distribution, while for antidementive drug treatment and PIM prescription logistic mixed models will be used. To account for the stochastic dependency of patients treated by the same GP, the GP will be included as random effect variable.
The follow up outcome variable at T 1 (twelve months after finishing the baseline) will be the dependent variable in these analyses; the study group is the predictor of interest, while the baseline value (T 0 ) of the outcome variable will be included as covariate to diminish residual variance and to account for inter-individual variance at baseline. Furthermore, sociodemographic variables (age, sex and living situation (alone vs. not alone)) are planned to be included as covariates, too. These variables can be supposed to contribute proportions of variance to the outcome variables which should be independent of possible study effects as the intervention cannot change age, sex or living situation.
Thus, the inclusion of these variables should result in decreased residual variance enhancing thereby the statistical power to detect differences between study groups. A positive intervention effect is then defined as a significant regression coefficient (one-sided test) of the study group variable. The pvalues will be interpreted one-sided as one-sided hypotheses are tested. The design of the DelpHi trial allows for multiple testing (five primary outcomes), therefore, additionally the Bonferoni corrected pvalues will be reported.
Sensitivity Analyses
Including the GP as random effect variable in the equation using random intercepts only implies that the effect of the GP on the outcome variable is independent of the effects of the predictors which may not be correct for the study group variable and the baseline variable of the outcome. Thus, to test the robustness of the potential treatment effect, in sensitivity analyses random slopes for the baseline variable of the outcome will be introduced into the models. Descriptively, these models allow for GP dependent treatment effect and thus will result in treatment estimates respecting the possibility of differentially collaborating GPs, thus assessing the robustness of the results regardless of a potentially present performance bias.
The treatment effect estimates from the different models will be compared descriptively against each other and, moreover, the random slopes models will be tested against the random intercept models via likelihood ratio tests. Note that these likelihood ratio tests are known to be overly conservative.
Furthermore, in the case of the metric outcomes, we will derive additionally confidence intervals and p-values via non-parametric bootstrapping using 2000 replications. These sensitivity analyses are planned to get confidence intervals and p-values independent on the parametric assumptions of Gaussian distributions and homoscedasticity. Especially in the case of neuropsychiatric symptoms, baseline analyses indicated a skewed distribution for the NPI scores.
Secondary Analyses
In secondary analyses, the above described statistical modelling will be performed stratified for the living situation (living alone vs. not living alone). As the intervention targets also the care-giver and the social context of a person suffering from dementia, it is very plausible that the effects of the intervention are different for persons living alone and persons living not alone. For example, the caregiver burden might response differentially to the intervention. Thus, effect sizes of the intervention for the efficacy endpoints will be derived once for persons living alone and once for persons not living alone. Additionally, to allow an inference-statistical assessment, a study-group living status interaction term will be introduced in the models explained above. A significant interaction term will be interpreted correspondingly that the intervention does not have the same effect for individuals living alone and individuals living not alone. 
Intention to Treat (ITT) Analyses
To control a possible attrition bias, intention to treat analyses will be performed using multiple imputation techniques for the imputation of missing data. The method of imputation was not defined in the first version of the analyses plan. It was defined in March 2016 after the study statistician had completed a workshop for the handling of missing data in the end of February in Stockholm (Metrika Consulting -The Nordic STATA Contributor).
Definition of the Analyses Set
The ITT analyses will be carried out on the subsample of baseline-sample with baseline data regarding the primary efficacy endpoint under consideration. Thus, individuals which dropped out during the baseline assessment before the efficacy endpoint was surveyed will be excluded from the intention to treat analyses as there is not the necessary data available to allow the imputation of the follow data.
Missing values in the follow-up variable of the primary efficacy outcome will be imputed if the baseline value is not missing. Hence the ITT analyses can be seen as partial ITT analyses. The attrition bias caused by drop-out between the measurement points will be controlled by the imputation. A possible attrition bias caused by drop-out during baseline assessment will be not controlled by the ITT analyses proposed here.
Methods of Imputation
The imputation model will be chosen congenial to the analyses model with the difference that the GP will be included as a fixed effect in the imputation model. Thus, the model of imputation will be a linear regression for the care-giver burden, quality of live and NPI and logistic for antidementive drug use and the PIM, including the respective baseline variable, age, sex, the living status and the study group variable as predictors. The method of imputation is chosen to be multiple imputations via chained equations, using 50 runs of imputations. Standardized effect sizes will be also computed from these imputations and compared to the estimates of the per protocol analyses. Note that an important statistical pre-requisite for the usage of imputations is that the missing of the outcome variable is stochastically independent from the value of the outcome variable at follow-up given its baseline value.
Primary Efficacy Analyses (ITT)
The ITT analyses will be performed following the schedule of the per protocol analyses with the only difference being that missing follow-up values will be imputed.
Sensitivity Analyses (ITT)
The sensitivity analyses described in the per protocol analyses are not feasible using multiple imputation for computational reasons (bootstrap, random slopes). We plan, however, to use a second imputation model (predictive mean matching) for sensitivity analyses to test the dependency of the results on the concrete imputation method. Thus, we will rerun the ITT analyses only with the difference that the imputation models (including the same variables as before) will be based on predictive mean matching. Again, 50 runs of imputations will be used.
Secondary Analyses (ITT)
The same analyses will be carried out as described in the per protocol analyses with the difference that missing values in the outcome variable at follow-up will be imputed.
Methods against Bias
Here, we will describe the statistical treatment of potential bias. The methods used in the design of DelpHi-trial to reduce a priori certain kind of bias will be not discussed. Three types of bias need special attention in the DelpHi trial: 
Selection Bias
Although the trial is randomized it is possible that there is selection bias leading to differential baseline values in the primary efficacy outcomes regarding control and intervention group. As the baseline value of the outcome variable is included as covariate in the primary analysis model, the effect sizes of the intervention are thereby independent of baseline differences. Regardless, we will screen the two study group on differences regarding primary and secondary outcome variables, sociodemographic variables and study parameters on differences using generalized linear mixed models with the baseline variable as dependent variable and the study group as predictor. The GP will be included as random effect. The model specification will be specified according the type of variable tested (e.g. logistic for binary variables, Gaussian for metric variables, poisson for count outcomes).
Attrition Bias
We will perform ITT analyses as described to reduce the impact of drop-out during the follow-up interval. To check, whether systematic drop-out during the baseline assessment may influence the results, we will run a drop-out analyses. To this point, we will fit multivariable logistic regressions with drop-out (yes/no) being the dichotomous outcome and the study group, sociodemographic and the screening value of the DEMTECT as predictors. These analyses will be performed three-times:
2) Drop-out due to death 3) Drop-out due to withdrawal of informed consent
If it would be possible to predict drop-out during baseline by study-group parameters, it would be possible that attrition bias is still present despite the ITT analyses. In this case, the results of the study have to be treated cautiously.
Performance Bias
As the DelpHi-Trial is conducted in the setting of primary care, the control of the treatment in the control group as "care as usual" is not possible. It could be that already the inclusion of a GP into the study will change the treatment of the included patient. This effect could easily mask potential intervention effects. Thus, a non-significant result cannot be easily interpreted. The treatment adherence of the GPs in the intervention group was evaluated and generally quite high. Nevertheless, it is very plausible that the GPs were different in their adherence to the study protocol. For this reason, we performed special sensitivity analyses (see section "per protocol analyses"). These sensitivity analyses deliver a weak test of the robustness of the effects despite the heterogeneity between the GPs.
Post Hoc Power Calculations
The actual power of the trial was assessed during the baseline sampling when first estimates of the ICCs where known, for reasons explained above. Table 1 gives the estimates for the ICC of the baseline values of the primary efficacy endpoints and the detectable intervention effect (power 80%)
given an assumed coefficient of variation of cluster sizes of 1, a baseline follow-up correlation of 0.6, a mean cluster size of 5 and 100 clusters (GP) included into analysis (total n=500). The power analyses were done with STATA 13/SE using the package clustersampsi. Note that the estimates reported in table 1 were derived while the baseline sampling was still ongoing. DCM is a model of collaborative care and defined in this study as a complex intervention aiming to provide "optimum care" by integrating multi-professional and multimodal strategies to improve patient-and caregiver related outcomes due to an individualization and optimization of treatment and care in dementia within the framework of the established health care and social service system. It was developed according to current guidelines 1, 2 and is targeted at the individual participant's level and was conducted by 6 nurses with dementia-specific training at the people´s homes. The nurses were supported by a computer-based intervention management system (IMS) to improve the systematic identification of patients and caregivers' unmet needs and the subsequent recommendation of interventions to address these needs. Training as well as software are described in more detail elsewhere 3, 4 The development of DCM was based on German guidelines 1,2 for evidence-based diagnoses and treatment of dementia, reviews of the literature as well as on meetings with experts in the field of dementia. The DCM focus on (1) management of treatment and care, (2) medication management and (3) caregiver support and education. For these pillars a comprehensive set of intervention modules was defined, which helps to ensure that PwD and their caregivers receive tailored interventions according to their individual needs. Each module consists of specific predefined trigger conditions, a subsequent intervention task as well as at least one criterion to monitor for successful task completion.
To support the nurses in facilitating and planning the interventions the computer-assisted IMS was used. The nurses conducted a baseline as well as an in-depth assessment usually at the person's home. Based on these data, the IMS generates an individual preliminary list for the respective subject with suggestions for specific intervention tasks. This list is discussed and finalized in a weekly interdisciplinary case conference (nurses, a nursing scientist, a neurologist/psychiatrist, a psychologist, and a pharmacist) to check adherence to the study protocol as well as to assess the adequateness of the predefined intervention modules. After the case conference the main results of the baseline and in-depth assessment as well as the finalized list of intervention tasks are summarized by the study nurse in a semi-standardized GP-information letter which contains (1) a cover letter that gives a brief description of the patient's social, physical and mental needs and resources as well as some prioritized suggestions for intervention (2) a standardized report of the most important outcomes of baseline and in-depth assessment and (3) a list of suggested intervention tasks. This letter is then discussed face-to-face between GP and nurse to establish an individual treatment plan.
Finally the GP decides whether he will conduct a suggested intervention task, delegates a task to the nurse or rates a task as "not necessary". During the first six months of the intervention period, the nurse conducts home visits at least monthly, taking all necessary steps to carry out her designated intervention tasks in close cooperation with the 
